Molecular mechanisms of Rapsyn regulating NMJ formation have made much progress, and Rapsyn mutation accounts for about 14%–27% of CMS cases [77, 81, 84–91]. The gene discussed is RAPSN; the disease is congenital myasthenic syndrome.